The abstract is read at the publisher; the summary is JClub's.
Morning intranasal ketamine markedly and durably reduced cataplexy in a 34-year-old man with narcolepsy type 1, with recurrence after stopping treatment.
- Why it matters: Current cataplexy therapies that target monoaminergic, histaminergic, and GABAergic pathways may be ineffective or poorly tolerated, leaving limited options for some patients.
- What they did: In orexin knockout mice with polysomnography in a crossover design, ketamine was compared with vehicle to test effects on cataplexy and sleep architecture.
- The result: Ketamine dramatically decreased time spent in cataplexy by -76% (p = 0.008) without altering sleep architecture, supporting further clinical investigation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.